Agios製藥 AGIO 深 滬
已收盤 02-06 16:00:00 美东时间
26.53
-0.040
-0.15%
華盛通- 最 高27.425
- 今 開27.03
- 成交量 115.16万股
- 最 低 26.50
- 昨 收 26.57
- 總市值 15.47亿
- 52周最高 46.00
- 市盈率 靜 2.28
- 換手率 1.97%
- 52周最低 22.24
- 委 比 -7.13%
- 總股本 5831.38万
- 歷史最高 138.85
- 量 比 1.32
- 振 幅 3.48%
- 歷史最低 15.77
- 每 手 1
- 風險率 5.37%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 拼多多、小鹏获Freedom上调目标价；多家大行首予Wealthfront"超配"评级，目标价最高23美元
今日重点评级关注：HC Wainwright & Co.：维持MetaVia Inc."买入"评级，目标价从12美元升至40美元；Canaccord Genuity：维持GH Research"买入"评级，目标价从35美元升至39美元
01-07 17:25
JP Morgan Maintains Neutral on Agios Pharmaceuticals, Raises Price Target to $25
JP Morgan analyst Tessa Romero maintains Agios Pharmaceuticals (NASDAQ:AGIO) with a Neutral and raises the price target from $20 to $25.
01-07 02:11
美股大行评级 | 潜在涨幅121.27%！HC Wainwright & Co.：Agios Pharmaceuticals获机构升目标价至62美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Agios Pharmaceuticals"买入"评级，目标价从48美元升至62美元；Leerink Partners：维持Agios Pharmaceuticals"跑赢大市"评级，目标价从34美元升至40美元
2025-12-29 10:27
美股牛股 | 奥麦罗制药涨超75%，YARTEMLEA药物获得FDA批准；德纳维制药涨超38%
奥麦罗制药涨超75%，YARTEMLEA药物获得FDA批准；德纳维制药涨超38%，获法国制药巨头22亿美元收购；Sidus Space涨超33%，获美国导弹防御局合同>>
2025-12-26 18:41
B of A Securities Maintains Buy on Agios Pharmaceuticals, Raises Price Target to $34
B of A Securities analyst Greg Harrison maintains Agios Pharmaceuticals (NASDAQ:AGIO) with a Buy and raises the price target from $32 to $34.
2025-12-24 21:21
FDA Approves Agios Drug For Thalassemia-Associated Anemia
FDA approves Agios' Aqvesme for anemia in alpha and beta thalassemia, backed by Phase 3 data and a REMS safety program.
2025-12-24 20:31
UiPath, Ramaco Resources And 3 Stocks To Watch Heading Into Wednesday
U.S. stock futures slightly lower. UiPath joins S&P Midcap 400, Agios receives FDA approval, Can Fite Biopharma announces reverse split.
2025-12-24 13:07
The FDA Has Not Yet Issued Regulatory Decision On Agios Pharmaceuticals' Supplemental New Drug Application For Mitapivat For Adult Patients With Non-transfusion-dependent And Transfusion-dependent Alpha- Or Beta-thalassemia, And It Remains Under Review.
The Prescription Drug User Fee Act (PDUFA) goal date issued by the FDA was December 7, 2025.Agios is collaborating closely with the FDA to finalize the labeling documents and Risk Evaluation and Mitigation Strategy
2025-12-08 20:10
美股大行评级 | 摩根大通上调百度至"超配"，目标价升至188美元！Navan获多家机构首予"买入"评级，目标价最高30美元
今日重点评级关注：巴克莱：维持Iovance Biotherapeutics"超配"评级，目标价从4美元升至9美元；BTIG：维持Cullinan Therapeutics"买入"评级，目标价从32美元升至38美元
2025-11-25 10:27
美股大行评级 | 最高130美元！11家大行集体上调沃尔玛目标价；戴康工业、Gap、罗斯百货等均或多家大行上调目标价
今日重点评级关注：Canaccord Genuity：维持Fractyl Health"买入"评级，目标价从6美元升至8美元；HC Wainwright & Co.：维持MediWound"买入"评级，目标价从31美元升至36美元
2025-11-24 11:23
